Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies
IJROBP Journal SA-CME activity for July 15, 2019 (Volume 104, Issue 4) provides practitioners with knowledge needed to appropriately select patients for stereotactic body radiotherapy and counsel them regarding efficacy and side effects.
Please click here to read the related journal article online.
This activity is available from June 21, 2019, through 11:59 p.m. Eastern time on June 20, 2021.
This program is designed to meet the interest of radiation oncologists and radiation oncology residents.
- Determine the clinical indications for and advantages of stereotactic body radiotherapy for prostate cancer.
- Identify the risk of side effects from stereotactic body radiotherapy for prostate cancer.
Anthony Zietman, MD, FASTRO is employed by Massachusetts General Hospital and Elsevier, receives compensation/remuneration/funding from the National Cancer Institute (NCI) and holds leadership positions at ABR and NCI.
Rahul D. Tendulkar, MD has no financial relationships with a commercial interest.
Daniel Spratt, MD receives compensation/remuneration/funding from the Prostate Cancer Foundation and Prostate Cancer NIH SPORE.
The person(s) above served as the developer(s) of this activity. Additionally, the Journal CME Task Force and CME/MOC Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $30
- Member: $25
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 2 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.